Abstract

Endothelial colony-forming cells (ECFC) are grown from circulating CD34+ progenitors present in adult peripheral blood, but during in vitro expansion part of the cells lose CD34. To evaluate whether the regulation of CD34 characterizes the angiogenic phenotypical features of PB-ECFCs, we investigated the properties of CD34+ and CD34− ECFCs with respect to their ability to form capillary-like tubes in 3D fibrin matrices, tip-cell gene expression, and barrier integrity. Selection of CD34+ and CD34− ECFCs from subcultured ECFCs was accomplished by magnetic sorting (FACS: CD34+: 95 % pos; CD34−: 99 % neg). Both fractions proliferated at same rate, while CD34+ ECFCs exhibited higher tube-forming capacity and tip-cell gene expression than CD34− cells. However, during cell culture CD34− cells re-expressed CD34. Cell-seeding density, cell–cell contact formation, and serum supplements modulated CD34 expression. CD34 expression in ECFCs was strongly suppressed by newborn calf serum. Stimulation with FGF-2, VEGF, or HGF prepared in medium supplemented with 3 % albumin did not change CD34 mRNA or surface expression. Silencing of CD34 with siRNA resulted in strengthening of cell–cell contacts and increased barrier function of ECFC monolayers as measured by ECIS. Furthermore, CD34 siRNA reduced tube formation by ECFC, but did not affect tip-cell gene expression. These findings demonstrate that CD34+ and CD34− cells are different phenotypes of similar cells and that CD34 (1) can be regulated in ECFC; (2) is positively involved in capillary-like sprout formation; (3) is associated but not causally related to tip-cell gene expression; and (4) can affect endothelial barrier function.Electronic supplementary materialThe online version of this article (doi:10.1007/s10456-016-9506-9) contains supplementary material, which is available to authorized users.

Highlights

  • Adequate regeneration of the tissue affected by ischemic insult relies on efficient angiogenesis that can be facilitated by tissue engineering or cell-based therapeutics involving endothelial cells (ECs)

  • While PB-Endothelial colony-forming cells (ECFC) colonies arise from CD34? cells [6], during subculturing both CD34? and CD34- ECFCs are encountered

  • The present study shows that CD34 was repressed in medium supplemented with newborn calf serum (NBCS) and human serum, and became re-expressed after exposure of ECFCs to medium supplemented with human serum albumin or platelet lysate

Read more

Summary

Introduction

Adequate regeneration of the tissue affected by ischemic insult relies on efficient angiogenesis that can be facilitated by tissue engineering or cell-based therapeutics involving endothelial cells (ECs). Endothelial colony-forming cells (ECFCs) are considered as the most suitable ECs type for regenerative angiogenesis [2] These cells, named as late outgrowth endothelial progenitor cells (EPCs) or blood-outgrowth endothelial cells (BOECs), differ from the early outgrowth CD14?/CD45? The ECFCs, which can be obtained from cord or peripheral blood, exhibit pronounced vascularization ability in vivo by physically incorporating into newly formed blood vessels [4]. Their neovascularization potency is accentuated in combination with stem/progenitors cells like mesenchymal stem cells or adipose-derived stem cells [5]. Previous studies revealed that ECFCs originate from the blood-derived mononuclear progenitor cell fraction expressing CD34 among other stem/progenitor cell surface markers such as CD31 or CD146 [6, 7] and are negative for CD14 or CD45

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call